BIOCHEMICAL CHARACTERISTICS OF CARBOHYDRATE AND LIPID METABOLISM DISORDERS IN FATTY LIVER DISEASE

Authors

  • Isroilova Nilufar Mirobid qizi Department of Biological Chemistry, Andijan State Medical Institute, Andijan, Uzbekistan Author

Keywords:

fatty liver disease, hepatic steatosis, carbohydrate metabolism, lipid metabolism, insulin resistance, de novo lipogenesis, atherogenic dyslipidemia, free fatty acids, triacylglycerols, clinical biochemistry.

Abstract

Fatty liver disease, clinically recognized as non-alcoholic or metabolic dysfunction-associated steatotic liver disease, represents a pervasive global health burden characterized by excessive intrahepatic triacylglycerol accumulation in the absence of secondary hepatotoxic causes. At the molecular level, the pathogenesis and progression of hepatic steatosis are governed by a profound, reciprocal disruption of systemic and intrahepatic carbohydrate and lipid metabolism. However, routine clinical evaluations frequently rely on isolated transaminase measurements, overlooking the intricate biochemical interplay between defective insulin signaling, unrestrained hepatic gluconeogenesis, and accelerated de novo lipogenesis. This comprehensive clinical-biochemical study investigates the specific biochemical features and diagnostic interrelations of carbohydrate and lipid metabolism disorders in patients diagnosed with fatty liver disease. A cohort of patients with ultrasonographically and biochemically confirmed hepatic steatosis was systematically evaluated alongside an age- and sex-matched healthy control group. Biochemical profiling encompassed the quantitative assessment of fasting plasma glucose, glycated hemoglobin, immunoreactive insulin, the homeostasis model assessment of insulin resistance index, serum free fatty acids, total cholesterol, triacylglycerols, high-density and low-density lipoprotein cholesterol fractions, and apolipoprotein B, paired with standard hepatobiliary cytolytic enzymes. The findings demonstrate that individuals with fatty liver disease exhibit severe peripheral and hepatic insulin resistance, fasting hyperinsulinemia, and elevated glycated hemoglobin levels, which directly drive a pronounced atherogenic dyslipidemia characterized by hypertriglyceridemia, elevated circulating free fatty acids, increased low-density lipoprotein cholesterol, and depleted high-density lipoprotein cholesterol concentrations. Furthermore, the homeostasis model assessment of insulin resistance index correlated strongly and positively with serum triacylglycerol and free fatty acid concentrations, as well as with alanine aminotransferase activity, while inversely correlating with high-density lipoprotein cholesterol levels. The study concludes that comprehensive, simultaneous profiling of carbohydrate and lipid metabolic indices provides superior insight into the biochemical severity of hepatocellular lipid overload, offering a highly sensitive tool for early cardiometabolic risk stratification and targeted therapeutic monitoring in fatty liver disease.

References

1.Rinella, M. E., Lazarus, J. V., Ratziu, V., Francque, S. M., Sanyal, A. J., Kanwal, F., & Newsome, P. N. (2023). A multisociety Delphi consensus statement on new fatty liver disease nomenclature. Hepatology, 78(6), 1966-1986.

2.Younossi, Z. M., Golabi, P., Paik, J. M., Henry, A., Van Dongen, C., & Henry, L. (2023). The global epidemiology of nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH): a systematic review. Hepatology, 77(4), 1335-1347.

3.Petersen, M. C., Vatner, D. F., & Shulman, G. I. (2017). Regulation of hepatic glucose metabolism in health and disease. Nature Reviews Endocrinology, 13(10), 572-587.

4.Brown, M. S., & Goldstein, J. L. (2008). Selective versus total insulin resistance: a pathogenic paradox. Cell Metabolism, 7(2), 95-96.

5.Donnelly, K. L., Smith, C. I., Schwarzenberger, S. J., Jessurun, J., Boldt, M. D., & Parks, E. J. (2005). Sources of fatty acids stored in liver and secreted via lipoproteins in patients with nonalcoholic fatty liver disease. The Journal of Clinical Investigation, 115(5), 1343-1351.

6.Softic, S., Cohen, D. E., & Kahn, C. R. (2016). Role of dietary fructose and hepatic de novo lipogenesis in fatty liver disease. Digestive Diseases and Sciences, 61(5), 1282-1293.

7.Ipsen, D. H., Lykkesfeldt, J., & Tveden-Nyborg, P. (2018). Molecular mechanisms of hepatic lipid accumulation in non-alcoholic fatty liver disease. Cellular and Molecular Life Sciences, 75(18), 3313-3327.

8.Chatrath, H., Vuppalanchi, R., & Chalasani, N. (2012). Dyslipidemia in patients with nonalcoholic fatty liver disease. Seminars in Liver Disease, 32(1), 22-29.

9.Deprince, A., Haas, J. T., & Staels, B. (2020). Dysregulated lipid metabolism links NAFLD to cardiovascular disease. Molecular Metabolism, 42, 101092.

10.Loomba, R., Friedman, S. L., & Shulman, G. I. (2021). Mechanisms and disease consequences of nonalcoholic fatty liver disease. Cell, 184(10), 2537-2564.

11.Buzzetti, E., Pinzani, M., & Tsochatzis, E. A. (2016). The multiple-hit pathogenesis of non-alcoholic fatty liver disease (NAFLD). Metabolism, 65(8), 1038-1048.

12.Lambert, J. E., Ramos-Roman, M. A., Browning, J. D., & Parks, E. J. (2014). Increased de novo lipogenesis is a distinct characteristic of individuals with nonalcoholic fatty liver disease. Gastroenterology, 146(3), 726-735.

13.Samuel, V. T., & Shulman, G. I. (2018). Nonalcoholic fatty liver disease as a nexus of metabolic and hepatic diseases. Cell Metabolism, 27(1), 22-41.

14.Watt, M. J., Miotto, P. M., De Nardo, W., & Montgomery, M. K. (2019). The liver as an endocrine organ—linking NAFLD and insulin resistance. Endocrine Reviews, 40(5), 1367-1393.

Downloads

Published

2026-11-06